Pro Bono Bio has a portfolio of in-market, approved and development products
In pain, FLEXISEQ® was launched in 2012 and line extensions are expected this year and beyond.
In haematology, we have four core products focused on the Factor VIII. LongAteTM (IV) has been approved in Russia; there are three development programmes. There is also a development programme for FVII.
In dermatology, we have launched six products and plan further launches this year.